Patents by Inventor Patrick Deluca

Patrick Deluca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10996039
    Abstract: A hand settable fuze interfaces with a servomotor to deploy a net from a projectile in flight. Prior to launch, a dial is rotated to both power on the fuze and set a preset delay. The projectile is then launched from a launcher system to deliver the stowed net rapidly and accurately toward a target. After the preset delay, the net is deployed from the projectile toward the target by operation of the servomotor.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: May 4, 2021
    Assignee: U.S. Government as Represented by the Secretary of the Army
    Inventors: Patrick DeLuca, Evan Young, Brent Beauseigneur, Daniel Kelly, Dexter Cook, Tomasz Blyskal, Lam Vo
  • Patent number: 8975284
    Abstract: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: March 10, 2015
    Assignee: US WorldMeds LLC
    Inventors: Ahmad Malkawi, Abeer M. Al-Ghananeem, Patrick DeLuca, George A. Digenis
  • Publication number: 20110160261
    Abstract: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
    Type: Application
    Filed: September 5, 2008
    Publication date: June 30, 2011
    Applicant: US WorldMeds, LLC
    Inventors: Ahmad Malkawi, Abeer Al-Ghananeem, Patrick DeLuca, George Digenis
  • Publication number: 20110015243
    Abstract: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
    Type: Application
    Filed: September 5, 2008
    Publication date: January 20, 2011
    Applicant: US WorldMeds, LLC
    Inventors: Ahmad Malkawi, Abeer Al-Ghananeem, Patrick DeLuca, George Digenis
  • Publication number: 20080081366
    Abstract: A lyophilized polynucleotide composition contains at least one polynucleotide and at least one cryoprotectant, wherein the ratio of the polynucleotide to cryoprotectant is from about 0.001 to about 1.0 part by weight polynucleotide per 1.0 part by weight of the cryoprotectant. This composition also contains from about 0.5 weight percent to about (6) weight percent water, based on the total weight of the final lyophilized polynucleotide composition. The polynucleotide composition of this invention is characterized by enhanced stability, in that it retains at least 90% supercoil over a time period of at least (10) days at a temperature of about 37° C. The lyophilized polynucleotide composition also has improved solubility. An improved process for lyophilization of polynucleotides employs a specific primary drying cycle, that results in the above-described stable, lyophilized polynucleotide composition.
    Type: Application
    Filed: August 24, 2007
    Publication date: April 3, 2008
    Applicant: Wyeth
    Inventors: Shankar Musunuri, Patrick DeLuca
  • Publication number: 20070122487
    Abstract: The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and/or derivatives thereof, a calicitonin, a parathyroid hormone (PTH), a bone morphogenic protein (BMP), an erythropoietin (EPO), an epidermal growth factor (EGF) or a growth hormone. This invention also relates to methods of using the composite microspheres, and methods of preparing same.
    Type: Application
    Filed: March 19, 2004
    Publication date: May 31, 2007
    Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Patrick Deluca, Ge Jiang, Byung Woo